Clinical characteristics of patients at start of iron chelation with DFO
Patient no. . | Diagnosis . | Age, y . | Liver iron level, μmol/g . | Ferritin level, μg/L . | TfS, % . | Transfused blood, U* . | Blood needs, U/mo . | Myocardial iron value, μmol/g . | Urinary iron level, mg/24 h . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDS, RARS | 58 | 501 | 3600 | 88 | 132 | 8.1 | 12.8 | 53.6 |
| 2 | MDS, RA | 67 | 521 | 4340 | 79 | 77 | 3.8 | 8.5 | 20.7 |
| 3 | MDS, RAEB | 63 | 558 | 1780 | 94 | 116 | 4.7 | 8.0 | 24.2 |
| 4 | MDS, RA + ERD | 47 | 403 | 2510 | 75 | 105 | 4.8 | 6.3 | 12.3 |
| 5 | MDS, RA | 64 | 540 | 5770 | 83 | 88 | 5.7 | 16.4 | 32.3 |
| 6 | MDS, RA | 46 | 558 | 3800 | 88 | 75 | 3.2 | 1.6 | 19.9 |
| 7 | MDS, RARS | 69 | 491 | 4790 | 102 | 90 | 4.0 | 12.8 | 35.2 |
| 8 | MDS, RA | 41 | 623 | 8715 | 100 | 254 | 2.9 | 21.2 | 43.5 |
| 9 | DBS | 37 | 388 | 2380 | 108 | 420 | 3.1 | 9.9 | 17.5 |
| 10 | MDS, RAEB-t | 65 | 626 | 7370 | 100 | 207 | 6.6 | 19.5 | 36.6 |
| 11 | CH | 41 | 479 | 1280 | 66 | 70 | 1.0 | 1.5 | 11.9 |
| 12 | MDS RA | 32 | 431 | 4000 | 107 | 84 | 6.0 | 10.1 | ND |
| 13 | AML CR | 34 | 468 | 2200 | 62 | 109 | 3.0 | 3.6 | 11.7 |
| 14 | MDS RA | 32 | 405 | 1740 | 84 | 44 | 3.0 | 1.3 | 9.9 |
Patient no. . | Diagnosis . | Age, y . | Liver iron level, μmol/g . | Ferritin level, μg/L . | TfS, % . | Transfused blood, U* . | Blood needs, U/mo . | Myocardial iron value, μmol/g . | Urinary iron level, mg/24 h . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDS, RARS | 58 | 501 | 3600 | 88 | 132 | 8.1 | 12.8 | 53.6 |
| 2 | MDS, RA | 67 | 521 | 4340 | 79 | 77 | 3.8 | 8.5 | 20.7 |
| 3 | MDS, RAEB | 63 | 558 | 1780 | 94 | 116 | 4.7 | 8.0 | 24.2 |
| 4 | MDS, RA + ERD | 47 | 403 | 2510 | 75 | 105 | 4.8 | 6.3 | 12.3 |
| 5 | MDS, RA | 64 | 540 | 5770 | 83 | 88 | 5.7 | 16.4 | 32.3 |
| 6 | MDS, RA | 46 | 558 | 3800 | 88 | 75 | 3.2 | 1.6 | 19.9 |
| 7 | MDS, RARS | 69 | 491 | 4790 | 102 | 90 | 4.0 | 12.8 | 35.2 |
| 8 | MDS, RA | 41 | 623 | 8715 | 100 | 254 | 2.9 | 21.2 | 43.5 |
| 9 | DBS | 37 | 388 | 2380 | 108 | 420 | 3.1 | 9.9 | 17.5 |
| 10 | MDS, RAEB-t | 65 | 626 | 7370 | 100 | 207 | 6.6 | 19.5 | 36.6 |
| 11 | CH | 41 | 479 | 1280 | 66 | 70 | 1.0 | 1.5 | 11.9 |
| 12 | MDS RA | 32 | 431 | 4000 | 107 | 84 | 6.0 | 10.1 | ND |
| 13 | AML CR | 34 | 468 | 2200 | 62 | 109 | 3.0 | 3.6 | 11.7 |
| 14 | MDS RA | 32 | 405 | 1740 | 84 | 44 | 3.0 | 1.3 | 9.9 |
In patient 9 the first MRI examination was performed after 9 months of iron chelation. In patient 8 the first estimation of myocardial iron was performed after 6 months of iron chelation. Normal range (mean ± 2 SD) for MRI liver iron is 1 to 15 μmol/g and for MRI myocardial iron, 0.1 to 5.7 μmol/g. Urinary iron excretion was measured at start of DFO treatment by use of DFO dosages as indicated in Figure 4. MDS indicates myelodysplastic syndrome; RARS, refractory anemia with ringed sideroblasts; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; ERD, end-stage renal disease; DBS, Diamond-Blackfan syndrome; RAEB-t, refractory anemia in transformation to AML; CH, chronic hemolysis of unknown etiology; ND, not determined; AML (CR), acute myeloid leukemia in complete remission; and TfS, iron saturation of serum transferrin.
Number of transfused blood units.